This is a Phase 1, open-label, dose-escalation and dose-expansion study to evaluate the
safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and clinical activity of
etrumadenant (AB928) in combination with zimberelimab (AB122) (an anti-PD-1 antibody) in
participants with advanced malignancies.
In the dose-escalation phase, escalating doses of etrumadenant in combination with
zimberelimab will be assessed in participants with advanced malignancies. Eligible
participants will receive oral administration of etrumadenant as well as IV infusion of
zimberelimab. The recommended dose for expansion (RDE) of etrumadenant will be determined
upon completion of the dose-escalation phase.
In the dose-expansion phase, etrumadenant at RDE in combination with zimberelimab may be
assessed in participants with advanced clear-cell renal cell carcinoma (RCC) or metastatic
castrate-resistant adenocarcinoma of the prostate (mCRPC).
Overall duration of treatment will depend on how well the treatment is tolerated. Treatment
may continue until unacceptable toxicity or progressive disease or other reasons specified in
1. Male or female participants ≥ 18 years
2. Must have at least 1 measurable lesion per RECIST v1.1.
3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
4. Must have received standard of care, including potentially curative available
therapies or interventions.
5. Confirm that an archival tissue sample is available and ≤ 6 months old; if not, a new
biopsy of a tumor lesion must be obtained. Biopsy must not put participant at undue
risk and procedure must not be more invasive than a core biopsy.
6. Adequate organ and marrow function
Dose escalation only:
7. Pathologically confirmed non-small cell lung cancer, squamous cell carcinoma of the
head and neck, renal cell carcinoma, breast cancer, colorectal cancer, melanoma,
bladder cancer, ovarian cancer, endometrial cancer, Merkel cell carcinoma, or
gastroesophageal cancer that is metastatic, advanced or recurrent with progression for
which no alternative or curative therapy exists or standard therapy is not considered
appropriate by the participant and treating physician (reason must be documented in
Dose expansion only:
8. Patients with advanced clear-cell RCC or mCRPC.
9. Clear-cell RCC patients may have received up to 2 prior lines of therapy, one of which
must have included an anti-PD-(L)1 based therapy and must not have progressed within
16 weeks during an anti-PD-(L)1 therapy.
10. mCRPC patients must have progressed during or following treatment with an androgen
synthesis inhibitor, and have also had one prior line of a taxane-containing regimen
or the physician and participant consider the taxane-containing regimen to be
inappropriate. mCRPC patients must be naive to any immunotherapy (including but not
limited to anti-PD-(L)1 or anti-CTLA-4 antogonists, sipuleucel-T, etc.).
1. Use of any live vaccines against infectious diseases (eg, influenza, varicella) within
4 weeks (28 days) of initiation of investigational product.
2. Underlying medical conditions that, in the Investigator's or Sponsor's opinion, will
make the administration of investigational product hazardous (eg, interstitial lung
disease, active infections requiring antibiotics, recent hospitalization with
unresolved symptoms) or obscure the interpretation of toxicity determination or AEs,
or concurrent medical condition requiring the use of immunosuppressive medications or
immunosuppressive doses of systemic or absorbable topical corticosteroids.
3. Has known psychiatric or substance abuse disorders that would interfere with
cooperation with the requirements of the trial.
4. Is pregnant or breastfeeding or expecting to conceive or father children within the
projected duration of the study, starting with the pre-screening or screening visit
through 90 days after the last dose of etrumadenant in combination with zimberelimab.
5. Any active or documented history of autoimmune disease, or history of a syndrome that
required systemic steroids or immunosuppressive medications, except for vitiligo or
resolved childhood asthma/atopy. Participants with asthma who require intermittent use
of bronchodilators (such as albuterol) will not be excluded from this study.
6. Prior malignancy active within the previous year except for locally curable cancers
that have been apparently cured, such as basal or squamous cell skin cancer,
superficial bladder cancer or carcinoma in situ of the cervix, breast, or prostate
7. Dose escalation: Prior treatment with an anti-PD-L1, anti-PD-1, anti-CTLA-4, or other
immune checkpoint inhibitor or agonist as a monotherapy or in combination;
8. Use of other investigational drugs (drugs not marketed for any indication) within 28
days or at least 5 half-lives (whichever is longer) before investigational product